Medicines labeled for the same conditions
Alternatives to semaglutide
35 other medicines are given the same way (oral) and in the same FDA class as semaglutide or labeled mainly for the same use (type 2 diabetes); 1 is in its class, GLP-1 receptor agonists: orforglipron; the others include 9 dipeptidyl peptidase 4 inhibitors, 8 sodium-glucose cotransporter 2 inhibitors and 5 sulfonylureas (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $20.89 per Foundayo 0.8 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as semaglutide?
The first 24 of the 35, the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| SemaglutideGLP-1 receptor agonist | this medicine | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued |
| OrforglipronGLP-1 receptor agonist · same class | Weight management | none listed | $20.89 per tablet 0.8 mg tablet | Yes | No current entry |
| Metforminbiguanide | Type 2 diabetes | 83 labelers | $0.0145 per tablet 500 mg tablet | Yes | No current entry |
| Glipizidesulfonylurea | Type 2 diabetes | 31 labelers | $0.0339 per tablet 5 mg tablet | No | No current entry |
| Glimepiridesulfonylurea | Type 2 diabetes | 29 labelers | $0.0507 per tablet 4 mg tablet | No | No current entry |
| Pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | 22 labelers | $0.0675 per tablet 15 mg tablet | Yes | No current entry |
| Glyburidesulfonylurea | Type 2 diabetes | 16 labelers | $0.0643 per tablet 5 mg tablet | No | A presentation being discontinued |
| Dapagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Type 2 diabetes | 8 labelers | $0.720 per tablet 10-1,000 mg tablet | Yes | No current entry |
| Metformin and sitagliptindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | 4 labelers | $1.76 per tablet 50 mg-1,000 mg tablet | Yes | No current entry |
| Sitagliptindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | 4 labelers | $3.77 per tablet 100 mg tablet | No | No current entry |
| Glyburide and metforminsulfonylurea | Type 2 diabetes | 11 labelers | $0.171 per unit 2.5-500 mg | Yes | No current entry |
| Glipizide and metforminsulfonylurea | Type 2 diabetes | 9 labelers | $0.242 per unit 2.5-250 mg | No | No current entry |
| Repaglinideglinide | Type 2 diabetes | 7 labelers | $0.0987 per tablet 1 mg tablet | No | No current entry |
| Nateglinideglinide | Type 2 diabetes | 9 labelers | $0.179 per tablet 60 mg tablet | No | No current entry |
| Acarbosealpha-glucosidase inhibitor | Type 2 diabetes | 6 labelers | $0.274 per tablet 100 mg tablet | No | No current entry |
| Metformin and pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | 5 labelers | $0.283 per unit 15-500 | Yes | No current entry |
| Alogliptindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | none listed | $4.96 per tablet 12.5 mg tablet | No | No current entry |
| Canagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $9.58 per tablet 150-1,000 mg tablet | Yes | No current entry |
| Alogliptin and pioglitazoneperoxisome proliferator receptor gamma agonist | Type 2 diabetes | none listed | $4.73 per tablet 25-15 mg tablet | Yes | No current entry |
| Empagliflozin and metforminsodium-glucose cotransporter 2 inhibitor | Type 2 diabetes | none listed | $5.60 per tablet 12.5-1,000 mg tablet | Yes | No current entry |
| Linagliptin and metformindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | 1 labeler | $8.44 per tablet 2.5 mg-1,000 mg tablet | Yes | No current entry |
| Canagliflozinsodium-glucose cotransporter 2 inhibitor | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $19.13 per tablet 100 mg tablet | No | No current entry |
| Metformin and saxagliptindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | 2 labelers | $9.65 per tablet 5-1,000 mg tablet | Yes | No current entry |
| Miglitolalpha-glucosidase inhibitor | Type 2 diabetes | 2 labelers | n/a | No | No current entry |
| Saxagliptindipeptidyl peptidase 4 inhibitor | Type 2 diabetes | 3 labelers | $1.04 per tablet 5 mg tablet | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Semaglutide: the full record
- label, generics, price, shortages, recalls
- Metformin vs semaglutide
- two records side by side
- Semaglutide vs sitagliptin
- two records side by side